AIM: Multiplikator P/S aimimmuno.com
Volatility for AIM ImmunoTech (AIM) is driven by the exclusivity of Ampligen RNA therapy for combating cancer and viruses. The company's price-to-sales ratio visualizes market demand, where 60.40 represents the current metric. While stability depends on grants and clinical trial outcomes, a critical reliance on a single product and external funding creates significant risks for the business model.
Rincian analitis perusahaan AIM ImmunoTech (AIM)
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi AIM ImmunoTech|AIM - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal aimimmuno.com|AIM - Utang perusahaan|Utang marang nilai buku AIM ImmunoTech|AIM - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan AIM ImmunoTech|Rasio cepet aimimmuno.com
- data bathi resik lan rasio valuasi:
AIM - Bathi resik perusahaan|Prakiraan bathi resik AIM ImmunoTech|AIM - Rasio rega marang bathi|Rasio prakiraan rega marang bathi AIM ImmunoTech, Inc.|AIM - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan AIM ImmunoTech|AIM - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan AIM ImmunoTech|AIM - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan aimimmuno.com|AIM - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep AIM ImmunoTech
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:AIM (AIM ImmunoTech, Inc.)
The P/S multiple determines the market value of one dollar of revenue, capturing the gap between market capitalization and actual cash inflows from sales. By analyzing the current P/S ratio, an investor assesses the monetization efficiency of AIM ImmunoTech biopharmaceutical developments, including the impact of laboratory ESG optimization and ethical standards on the business's market attractiveness and the growth rate of its fundamental value.
Pesaing AIM ImmunoTech
ARGX - Rega marang dodolan|Multiplikator P/S BNTX (BioNTech)|Multiplikator P/S Abivax Pharma ABVX|ADMA Bio - Multiplikator P/S|Koefisien rega marang pendapatan Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan kiniksa.com|Kapitalisasi marang pendapatan GRFS|ADPT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CLDX|Koefisien rega marang pendapatan Aurinia Corp|Rasio rega marang pendapatan BioCryst BCRX|VERA - Kapitalisasi marang pendapatan|DNTH - Rasio rega marang pendapatan|Pharvaris NV (PHVS) - Kapitalisasi marang pendapatan|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|Tourmaline (TRML) - Multiplikator P/S|Rasio rega marang pendapatan Precigen, Inc.|Rasio kapitalisasi marang pendapatan PHAR (pharming.com)|Rasio rega marang pendapatan Nektar Therapeutics Inc. (NKTR)|UPB - Rega marang dodolan|Zenas Biopharma, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan IMNM (Immunome Bio)|Gossamer Bio, Inc. - Multiplikator P/S|Rega marang dodolan kalvista.com|SEPN: Multiplikator P/S|Kapitalisasi marang pendapatan Pieris Pharma|SVRA (Savara Corp) - Multiplikator P/S|RIGL: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ANAB|Multiplikator P/S astriatx.com (ATXS)|Multiplikator P/S ENGN (enGene)|Koefisien rega marang pendapatan RAPT Therapeutics Inc. (RAPT)|JBIO - Rasio rega marang pendapatan|Aclaris Therapeutics, Inc (ACRS) - Kapitalisasi marang pendapatan|Kyverna Therapeutics (KYTX) - Rasio rega marang pendapatan|Rasio rega marang dodolan TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Multiplikator P/S|VTYX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S THTX|Multiplikator P/S Avalo Therapeutics Inc (AVTX)|Rasio rega marang pendapatan Eledon Pharmaceuticals ELDN|Rasio kapitalisasi pasar marang pendapatan AGEN|CLYM - Rasio rega marang pendapatan|Zura Bio Ltd (ZURA) - Kapitalisasi marang pendapatan|ATYR: Multiplikator P/S|Adagene Inc. (ADAG) - Multiplikator P/S|Kapitalisasi marang pendapatan IMA|STTK: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EQ|Koefisien rega marang pendapatan connectbiopharm.com|Rasio rega marang pendapatan Immunic IMUX|ATRA - Kapitalisasi marang pendapatan|IFRX - Rasio rega marang pendapatan|x4pharma.com (XFOR) - Kapitalisasi marang pendapatan|ACET (adicetbio.com) - Kapitalisasi marang pendapatan|Celularity (CELU) - Multiplikator P/S|Rasio rega marang pendapatan INmune Bio Corp|Rasio kapitalisasi marang pendapatan BRNS (Barinthus Biotherapeutics Corp)|Multiplikator P/S KZR|SABS - Rega marang dodolan|Multiplikator P/S AKTX (Akari Therapeutics Plc)|Multiplikator P/S Enlivex Therapeutics Ltd ENLV|Q32 Bio Corp - Multiplikator P/S|Koefisien rega marang pendapatan GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan ibioinc.com|Kapitalisasi marang pendapatan CARM|XTLB: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BOLT|Koefisien rega marang pendapatan hcwbiologics.com|Rasio rega marang pendapatan Aptevo Therapeutics Inc. APVO|ADTX - Kapitalisasi marang pendapatan|GRI - Rasio rega marang pendapatan|XORTX Therapeutics Inc (XRTX) - Kapitalisasi marang pendapatan|HIND (ReShape Lifesciences) - Kapitalisasi marang pendapatan|Revelation Biosciences Corp (REVB) - Multiplikator P/S|Rasio rega marang pendapatan Indaptus Therapeutics|Rasio kapitalisasi marang pendapatan SCNI (scinai.com)|Rasio rega marang pendapatan CalciMedica, Inc. (CALI)|AFMD - Rega marang dodolan|Allakos - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan HOOK (HOOKIPA Pharma, Inc.)|IGM Bio - Multiplikator P/S|Rega marang dodolan iteostherapeutics.com|OCEA: Multiplikator P/S|Kapitalisasi marang pendapatan TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
